
Corey Goodman
QuietNamed in filings at Venbio Global StrategicOn the current fund
- Board seats filed

Named in filings at Venbio Global StrategicOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Axonis Therapeutics | Biotech & pharma | October 2024 | None on file |
| INSAMO | Biotech & pharma | March 2023 | Playground Global |
| FOG PHARMACEUTICALS | Biotech & pharma | November 2022 | Transformation Capital |
| Attralus | Biotech & pharma | August 2021 | None on file |
| Tallac Therapeutics | Biotech & pharma | June 2020 | None on file |
| NFlection Therapeutics | Biotech & pharma | December 2016 | None on file |
| Checkmate Pharmaceuticals | Biotech & pharma | August 2015 | Sofinnova Venture Partners |
| Alexo Therapeutics | Biotech & pharma | May 2015 | None on file |
| Mirna Therapeutics | Biotech & pharma | March 2015 | None on file |
| Solstice Biologics | Biotech & pharma | September 2014 | Cure Ventures |
| LIMERICK BIOPHARMA | Biotech & pharma | January 2012 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The category is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Categories of companies where filings name Corey Goodman on the board, based on 11 filed seats with a verified or cited source.